These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1322 related items for PubMed ID: 8982148

  • 61. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [Abstract] [Full Text] [Related]

  • 62. Cellular effects of hydroxyurea in Hb SC disease.
    Steinberg MH, Nagel RL, Brugnara C.
    Br J Haematol; 1997 Sep; 98(4):838-44. PubMed ID: 9326175
    [Abstract] [Full Text] [Related]

  • 63. Hydroxyurea and erythropoietin therapy in sickle cell anemia.
    Goldberg MA, Brugnara C, Dover GJ, Schapira L, Lacroix L, Bunn HF.
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):74-81. PubMed ID: 1379376
    [Abstract] [Full Text] [Related]

  • 64. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N.
    Pediatr Nurs; 2006 Jun; 32(6):541-3. PubMed ID: 17256291
    [Abstract] [Full Text] [Related]

  • 65. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.
    Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw MA, Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    J Pain Symptom Manage; 2010 Dec; 40(6):870-82. PubMed ID: 20864308
    [Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA, Diaku-Akinwunmi IN, Ojewunmi OO, Bolarinwa AB, Adekile AD.
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J, HOPE Trial Investigators.
    N Engl J Med; 2019 Aug 08; 381(6):509-519. PubMed ID: 31199090
    [Abstract] [Full Text] [Related]

  • 71. Characterization of a cohort of Angolan children with sickle cell anemia treated with hydroxyurea.
    Santos B, Ginete C, Gonçalves E, Delgadinho M, Miranda A, Faustino P, Arez AP, Brito M.
    Blood Cells Mol Dis; 2024 Mar 08; 105():102822. PubMed ID: 38215581
    [Abstract] [Full Text] [Related]

  • 72. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo.
    Ballas SK, Dover GJ, Charache S.
    Am J Hematol; 1989 Oct 08; 32(2):104-11. PubMed ID: 2757007
    [Abstract] [Full Text] [Related]

  • 73. [Sickle cell anemia in children: value of hydroxyurea in severe forms].
    Oury AP, Hoyoux C, Dresse MF, Chantraine JM.
    Arch Pediatr; 1997 Sep 08; 4(9):839-44. PubMed ID: 9345564
    [Abstract] [Full Text] [Related]

  • 74. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.
    Am J Hematol; 2000 May 08; 64(1):26-31. PubMed ID: 10815784
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
    Barbu EA, Dominical VM, Mendelsohn L, Thein SL.
    PLoS One; 2019 May 08; 14(12):e0226583. PubMed ID: 31869367
    [Abstract] [Full Text] [Related]

  • 78. Impact of telehealth visits on hydroxyurea response in sickle cell anemia.
    Shaner S, Hilliard L, Howard T, Pernell B, Bhatia S, Lebensburger J.
    Pediatr Blood Cancer; 2021 Dec 08; 68(12):e29354. PubMed ID: 34532949
    [Abstract] [Full Text] [Related]

  • 79. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 80. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
    Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, Iyer RV, Sarnaik S, Rogers ZR, Wang WC, BABY HUG Investigators.
    Pediatr Blood Cancer; 2012 Oct 14; 59(4):675-8. PubMed ID: 22190441
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.